Title |
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
|
---|---|
Published in |
OncoTargets and therapy, October 2016
|
DOI | 10.2147/ott.s98347 |
Pubmed ID | |
Authors |
Antonio Passaro, Chiara Lazzari, Niki Karachaliou, Gianluca Spitaleri, Alessia Pochesci, Chiara Catania, Rafael Rosell, Filippo de Marinis |
Abstract |
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
Unknown | 68 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 17% |
Researcher | 12 | 17% |
Other | 8 | 12% |
Student > Bachelor | 6 | 9% |
Student > Postgraduate | 5 | 7% |
Other | 9 | 13% |
Unknown | 17 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 28% |
Biochemistry, Genetics and Molecular Biology | 10 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
Nursing and Health Professions | 3 | 4% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 5 | 7% |
Unknown | 22 | 32% |